期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

mTOR信号通路与胰腺癌研究进展 被引量：5

下载PDF
导出
摘要 雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)信号通路在胰腺癌中过度激活,可作为胰腺癌的靶向治疗的靶点。近年来研究显示,雷帕霉素及衍生物无论是单药使用还是和其他细胞毒性药物联合使用,都能明显抑制胰腺癌生长,mTOR抑制剂在胰腺癌的治疗中显示出良好的应用前景。本文就mTOR信号转导通路及mTOR抑制剂在胰腺癌治疗中的临床应用前景进行综述。
作者 王得龙 李勇
机构地区 南昌大学第一附属医院普外科
出处 《南昌大学学报（医学版）》 CAS 2016年第2期92-95,共4页 Journal of Nanchang University：Medical Sciences
关键词 胰腺癌 MTOR信号通路 MTOR抑制剂
分类号 R735.9 [医药卫生—肿瘤]
  • 相关文献

参考文献28

  • 1Liao W C,Tu Y K,Wu M S,et al. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-re sponse meta-analysis[J]. BMJ ,2015,349 :g7371.
  • 2Long J, Luo G P, Xiao Z W, et al. Cancer statistics:current diagno- sis and treatment of pancreatic cancer in Shanghai,China[J]. Cane er Lett,2014,346(2) :273-277.
  • 3Foster K G, Fingar D C. Mammalian target of rapamycin (mTOR) conducting the cellular signaling symphony[J]. J Bid Chem, 2010, 285(19) : 14071-14077.
  • 4Gomez Pinillos A, Ferrari A C. mTOR signaling pathway and roTOR inhibitors in cancer therapy[J]. Hematol Oncol Clin North Am,2012,26(3) :483-505.
  • 5Zaytseva Y Y, Valentino J D, Gulhati P, et al. mTOR inhibitors in cancer therapy[J]. Cancer Lett, 2012,319 (1) : 1-7.
  • 6Cho C H. Frontier of epilepsy research - mTOR signaling path way[J]. Exp Mol Med,2011,43(5) :231-274.
  • 7Mabuchi S, Kuroda H, Takahashi R, etal. The PI3K/AKT/ mTOR pathway as a therapeutic target in ovarian cancer[J]. Gynecol Oncol, 2015,137 ( 1 ) : 173-179.
  • 8Han D, Li S J,Zhu Y T, et al. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer[J]. Asian Pac J Cancer Prey,2013,14(7) :4033-4039.
  • 9齐观云,李文林,石小玉.磷酸腺苷依赖的蛋白激酶在自噬通路中作用的研究进展[J].南昌大学学报（医学版）,2014,54(2):78-82. 被引量：4
  • 10Javle M M,Shroff R T,Xiong H,et al. Inhibition of the mam- malian target of rapamyein (roTOR) in advanced pancreatic cancer:results of two phase II studies [J]. BMC Cancer, 2010,14(10) :368-374.

二级参考文献85

  • 1陈樑,张红锋.mTOR信号通路与癌症治疗[J].生命的化学,2005,25(2):127-129. 被引量：7
  • 2Law BK.Rapamycin:an anti-cancer inmunosuppressant? Crit Rev Oncol Hematol,2005,56:47-60.
  • 3Shaw RJ,Bardeesy N,Manning BD,et al.The LKB1 tumor suppressor negatively regulates mTOR signaling.Cancer Cell,2004,6:91-89.
  • 4Inoki K,Corradetti MN,Guan KL.Dysregulation of the TSC-mTOR pathway in human disease.Nat Genet,2005,37:19-24.
  • 5Chan S.Targeting the mammalian target of rapamycin (mTOR):a new approach to treating cancer.Br J Cancer,2004,91:1420-1424.
  • 6Mohi MG,Boulton C,Gu TL,et al.Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.Proc Natl Acad Sci USA,2004,101:3130-3135.
  • 7Akcakanat A,Sahin A,Shaye AN,et al.Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases.Cancer,2008,112:2352-2358.
  • 8Yan J,Kuroyanagi H,Tomemori T,et al.Mouse ULK2,a novel member of the UNC-51-like protein kinases:unique features of functional domains.Oncogene,1999,18:5850-5859.
  • 9Chan EY,Longatti A,McKnight NC,et al.Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism.Mol Cell Biol,2009,29:157-171.
  • 10Soroceanu L,Kharbanda S,Chen R,et al.Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma.Proc Natl Acad Sci USA,2007,104:3466-3471.

共引文献14

同被引文献70

引证文献5

二级引证文献14

南昌大学学报（医学版）
2016年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部